Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17356501 | 0.87 | HTR2A (0.40) | HTR2ASLC6A4KCNH2EPHX2PTPN7 | |
| SCHEMBL17352172 | 0.87 | HTR2A (0.36) | HTR2ASLC6A4KCNH2EPHX2PTPN7 | |
| SCHEMBL17356491 | 0.86 | TRPM8 (0.38) | HTR2ASLC6A4KCNH2EPHX2CDK8 | |
| SCHEMBL17356512 | 0.86 | SMN1; SMN2 (0.37) | HTR2ASLC6A4KCNH2EPHX2CDK8 | |
| SCHEMBL17356506 | 0.85 | PTPN7 (0.40) | HTR2ASLC6A4KCNH2EPHX2PTPN7 | |
| SCHEMBL17356492 | 0.84 | GAA (0.39) | PTPN7DUSP3 | |
| SCHEMBL17355831 | 0.82 | TDP1 (0.40) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL17356437 | 0.80 | ACHE (0.47) | HTR2ASLC6A4KCNH2PTPN7DUSP3 | |
| SCHEMBL17356472 | 0.80 | CDK8 (0.44) | HTR2ASLC6A4KCNH2EPHX2PTPN7 | |
| SCHEMBL17352167 | 0.80 | MAPT (0.44) | HTR2ASLC6A4KCNH2EPHX2PTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | UBE INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | UBE INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | HCN2, SCO2, HCN1 | HTR2A 4567/4885SLC6A4 2741/4885KCNH2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.